Endari (oral pharmaceutical grade L-glutamine) is an amino acid with antioxidant properties indicated to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients 5 years of age and older. It is a precursor for nicotinamide adenine dinucleotide (NAD), which is deficient in patients with SCD. A definitive mechanism of action is not yet defined, but Endari may benefit patients with SCD by increasing the activity of NAD synthesis, thus countering the oxidant-dependent pathophysiology of sickled red blood cells.

If you have a Hayes login, click here to view the full report on the Knowledge Center.